DJO Global Inc.’s business unit, DJO Surgical, signed a license agreement with the University of Utah that will enable DJO Surgical to develop percutaneous osseointegrated prostheses for transfemoral amputees, according to a press release.
Developed by Roy Bloebaum, PhD, a research professor of the department of orthopaedics at the University of Utah, and colleagues, the percutaneous osseointegrated prosthesis (POP) uses DJO Surgical’s titanium P2 porous coating as the bone in-growth as well as the seal material on the implant to prevent bacteria from entering the body. The researchers found no infections after 1 year and excellent mechanical strength in a preliminary study. Development work on the human implant has already started and clinical trials are expected to begin in approximately 2 years.
“We are excited to sign this partnership agreement with the University of Utah and Dr. Bloebaum,” Bryan Monroe, senior vice president and general manager of DJO Surgical, said in the release. “With the combination of our proprietary titanium P2porous coating and Dr. Bloebaum’s unique approach for POP, we believe that we have developed a winning solution that will have a monumental impact on the lives of amputees.”
